Oryzon Genomics SA
Research Oryzon Genomics SA (ORY) on Bullrun: market cap EUR 231.94M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerORY
- ExchangeMC
- CountrySpain
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 231.94M
- Financial periodQ2 2026
- RevenueEUR 0
- Net income-EUR 138.90K
Valuation Snapshot
latest market cap is EUR 231.94M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 2.27M | n/a | n/a | n/a | EUR 28.35M | EUR 7.63M | EUR 117.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 231.94M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oryzon Genomics SA's market cap?
Oryzon Genomics SA's market capitalization is EUR 231.94M.
What does Oryzon Genomics SA do?
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases.